Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well evaluating circulating tumor deoxyribonucleic acid (ctDNA) works to guide therapy-change decisions in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic). This study wants to learn if small pieces of DNA associated with a tumor (called circulating tumor DNA, or ctDNA) can be detected in investigational blood tests during the course of standard chemotherapy treatment for breast cancer, and whether information from such investigational ctDNA blood testing could possibly be used as an early indication of chemotherapy treatment failure. It is hoped that additional information from investigational blood testing for ctDNA could help doctors to switch more quickly from a standard chemotherapy treatment that typically has significant side effects and which may not be working, to a different standard treatment regimen against TNBC, called sacituzumab govitecan. Sacituzumab govitecan is a monoclonal antibody, called hRS7, linked to a chemotherapy drug, called irinotecan. hRS7 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers irinotecan to kill them. Studying ctDNA may assist doctors to change therapy earlier if needed, and may improve health outcomes in patients with metastatic TNBC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi, który dał przerzuty do innych części ciała (stadium IV).
- •Rak, który nie reaguje na hormony (ER, PR ujemny) ani HER2 (HER2 ujemny).
- •Rak, który nie jest wrażliwy na leczenie wspomagające odporność (PD-L1 ujemny).
- •Choroba, którą można zmierzyć za pomocą badań obrazowych (np. tomografii).
- •Pacjent ma 18 lat lub więcej.
- •Ogólny stan zdrowia pozwala na umiarkowaną aktywność (grupa ECOG 0-2).
- •Pacjent rozumie i zgadza się wziąć udział w badaniu.
- •Pacjent nie był wcześniej leczony chemioterapią z powodu choroby, która dała przerzuty.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Vanderbilt University/Ingram Cancer Center
Nashville, United States
Trial contact
Vanderbilt-Ingram Services for Timely Access
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.